PLAU and breast carcinoma: Urokinase-type plasminogen activator (PLAU) is associated with increased risk of metastasis in breast cancer [70] and is considered as the strongest indicator of poor prognosis in patients with metastatic breast cancer (Figure 3 in [126]).